MBRX

Maxim Group analyst Jason McCarthy maintained a Buy rating on Moleculin Biotech (MBRX - Research Report) yesterday and set a price target of $5.00. The company's shares closed yesterday at $0.94.McCarthy covers the Healthcare sector, focusing on stocks such as Immutep, Actinium Pharmaceuticals, and Daré Bioscience. According to TipRanks, McCarthy has an average return of -38.8% and a 14.29% success rate on recommended stocks. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Moleculin Biotech with a $10.50 average price target.See the top stocks recommended by analysts >>The company has a one-year high of $2.47 and a one-year low of $0.82.
https://www.tipranks.com/news/blurbs/moleculin-biotech-mbrx-receives-a-buy-from-maxim-group-2?utm_source=advfn.com&utm_medium=referral